Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 2
ClinicalTrials.gov
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
INTERVENTIONAL
Inicio: 5 de jul de 2023
ID: NCT05727176
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.
INTERVENTIONAL
Inicio: 16 de abr de 2025
ID: NCT06866405
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
INTERVENTIONAL
Inicio: 1 de may de 2014
ID: NCT01984684
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).
INTERVENTIONAL
Inicio: 14 de jul de 2022
ID: NCT05126277
Completado
Fase 3
ClinicalTrials.gov
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19
INTERVENTIONAL
Inicio: 9 de sept de 2021
ID: NCT05047601
Terminado
Fase 3
ClinicalTrials.gov
A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma
INTERVENTIONAL
Inicio: 13 de dic de 2018
ID: NCT03629249
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
INTERVENTIONAL
Inicio: 28 de dic de 2018
ID: NCT03650114
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)
INTERVENTIONAL
Inicio: 25 de feb de 2019
ID: NCT03713632
Reclutando
Fase 3
ClinicalTrials.gov
A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)
INTERVENTIONAL
Inicio: 30 de may de 2022
ID: NCT05183646
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
INTERVENTIONAL
Inicio: 21 de may de 2020
ID: NCT04379713
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
INTERVENTIONAL
Inicio: 25 de abr de 2016
ID: NCT02603432
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
INTERVENTIONAL
Inicio: 1 de jun de 2016
ID: NCT02767804
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Dose-finding Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
INTERVENTIONAL
Inicio: 1 de ago de 2018
ID: NCT03437278
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
INTERVENTIONAL
Inicio: 12 de dic de 2016
ID: NCT02946463
Completado
Fase 2
ClinicalTrials.gov
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
INTERVENTIONAL
Inicio: 29 de ago de 2017
ID: NCT03056755
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)
INTERVENTIONAL
Inicio: 13 de jun de 2016
ID: NCT02791230
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
INTERVENTIONAL
Inicio: 12 de dic de 2019
ID: NCT04023552
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
INTERVENTIONAL
Inicio: 11 de abr de 2014
ID: NCT01892345
Activo, no recluta
Fase 3
ClinicalTrials.gov
A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
INTERVENTIONAL
Inicio: 31 de ago de 2021
ID: NCT05035212
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
INTERVENTIONAL
Inicio: 30 de nov de 2017
ID: NCT03259074
Anterior
1
...
7
8
9
...
434
Siguiente
Filtros